SOUTH SAN FRANCISCO, CA--(Marketwire - May 29, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing data from its Phase I/II clinical trial evaluating its drug candidate SB-743921 is planned to be presented at the 10th International Conference on Malignant Lymphoma, at the Palazzo Dei Congressi in Lugano, Switzerland, June 4-7, 2008. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division.
